Kommentar
In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo
Annals of Internal Medicine · 2024
DOI: 10.7326/j23-0122 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Tanvi Gupta und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Health Science Center at Houston, Houston, Texas, USA (T.G., B.D.C.). Hauptthemen laut MEDLINE: Irritable Bowel Syndrome.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Irritable Bowel SyndromeHumansAmitriptylineDouble-Blind MethodPrimary Health CareTreatment OutcomeRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic
Substanzen
Amitriptyline
Autor:innen und Institutionen
- University of Texas Health Science Center at Houston, Houston, Texas, USA (T.G., B.D.C.).
Zitieren
APA
Gupta, T., & Cash, B. D. (2024). In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo. Annals of Internal Medicine. https://doi.org/10.7326/j23-0122
Vancouver
Gupta T, Cash BD. In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo. Annals of Internal Medicine. 2024. doi:10.7326/j23-0122
BibTeX
@article{Gupta2024,
author = {Gupta, Tanvi and Cash, Brooks D},
title = {In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo},
journal = {Annals of Internal Medicine},
year = {2024},
doi = {10.7326/j23-0122}
}
EUVIMED